Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in ...

9 September 2026 · By · Wire by Fusion42

Published

9 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biomarin.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

BioMarin announced positive Phase 3 trial results showing VOXZOGO significantly improves growth measures in children with hypochondroplasia and submitted a supplemental NDA to the FDA for expanded approval.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Approval of VOXZOGO for hypochondroplasia will create a new rare-disease market for you if you develop growth disorder therapies. Your competitive edge lies in targeting rare paediatric conditions with unmet needs ahead of broader approvals.

◆ Coverage

1 source · 9 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialdrug-approvalrare-diseasegrowth-disordersFDA-submission